SLC7A5 and neoplasm: However, high expression of SLC7A5 in tumor cells predicts reduced expression of immune-related genes, reduced immune cell infiltration, and poor efficacy of immunotherapy.271 Another bioinformatics analysis for breast cancer reached a similar conclusion.272 In addition, BCAT isoenzymes may serve as markers of tumor TME status.